Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice

Shintaro Hirata, Wanying Li, Satoshi Kubo, Shunsuke Fukuyo, Yasushi Mizuno, Kentaro Hanami, Norifumi Sawamukai, Kunihiro Yamaoka, Kazuyoshi Saito, Nadine A. Defranoux, Yoshiya Tanaka

Research output: Contribution to journalArticle

6 Citations (Scopus)


Objective: Evaluate the association between the multi-biomarker disease activity (MBDA) score and radiographic progression in patients with rheumatoid arthritis (RA) treated with tumor necrosis factor (TNF)-α inhibitors. Methods: Change (Δ) in modified total Sharp score (mTSS) over 52 weeks and disease activity scores were examined retrospectively by Spearman's rank correlation coefficient in patients (N = 83) with RA initiating TNF-inhibitor treatment. Relative risk (RR) of ΔmTSS >0.5 for low MBDA score and 28-joint count disease activity score (DAS28) categories and associations between ΔmTSS and MBDA score categories conditional on DAS28 categories were assessed. Results: At 52 weeks, 34% of patients had ΔmTSS >0.5 and 12% had ΔmTSS >3. Strongest correlations were observed between ΔmTSS and MBDA score (r = 0.47) or DAS28 (r = 0.42) at Week 24 and for area under the curve at Week 52 (MBDA score: r = 0.44, DAS28: r = 0.41), all p 0.5 for moderate/high MBDA score (≥30) or DAS28 (>3.2) were 6.6 (p 0.5 at 52 weeks when MBDA score was ≥30 (p 

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalModern Rheumatology
Publication statusAccepted/In press - 2016 Mar 22



  • Biomarkers
  • MBDA score
  • Radiographic progression
  • Rheumatoid arthritis
  • TNF inhibitor

ASJC Scopus subject areas

  • Rheumatology

Cite this